Does SGLT2i use reduce the primary composite outcome in CHF patients undergoing TAVR?
In patients with heart failure undergoing TAVR, the use of SGLT2 inhibitors did not significantly reduce the risk of the primary composite outcome at 6 months or 1 year.
Among CHF patients undergoing TAVR, SGLT2i use was not associated with a reduced risk of the primary composite outcome at 6-months and 1-year intervals.
Yasmin et al. (Sun,) studied this question.